Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis.
暂无分享,去创建一个
Mark A Westwood | Dudley J Pennell | D. Pennell | M. Tanner | R. Galanello | A. Piga | E. Gotsis | M. Westwood | Gillian Smith | Renzo Galanello | Antonio Piga | Mark A Tanner | Vasili Berdoukas | Markissia Karagiorga | Vasili Ladis | Athanassios Aessopos | Efstathios D Gotsis | Gill C Smith | Beatrix Wonke | B. Wonke | V. Ladis | A. Aessopos | V. Berdoukas | M. Karagiorga
[1] A. Hoffbrand,et al. Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients , 2003, British journal of haematology.
[2] Marvin D Nelson,et al. Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease. , 2004, Blood.
[3] G. D’Amico,et al. Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial. , 2002, Blood cells, molecules & diseases.
[4] D. Pennell,et al. Normalized Left Ventricular Volumes and Function in Thalassemia Major Patients with Normal Myocardial Iron. , 2005 .
[5] Mark A Westwood,et al. Interscanner reproducibility of cardiovascular magnetic resonance T2* measurements of tissue iron in thalassemia , 2003, Journal of magnetic resonance imaging : JMRI.
[6] Dudley J Pennell,et al. Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy. , 2002, The American journal of cardiology.
[7] A. Cnaan,et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. , 2004, Haematologica.
[8] S. Yusuf,et al. Effects of the Angiotensin Converting Enzyme Inhibitor Enalapril on the Long‐term: Progression of Left Ventricular Dysfunction in Patients With Heart Failure , 1992, Circulation.
[9] D. Krikler,et al. Heart disease: A textbook of cardiovascular medicine , 1992 .
[10] D. Pennell,et al. Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance , 2004, British journal of haematology.
[11] M. Cappellini,et al. Survival and Disease Complications in Thalassemia Major , 1998, Annals of the New York Academy of Sciences.
[12] J. Cohn,et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. , 1996, The New England journal of medicine.
[13] J. Tripp,et al. Magnetic-susceptibility measurement of human iron stores. , 1982, The New England journal of medicine.
[14] A. Morabito,et al. Potential Myocardial Iron Content Evaluation by Magnetic Resonance Imaging in Thalassemia Major Patients Treated with Deferoxamine or Deferiprone During a Randomized Multicenter Prospective Clinical Study , 2003, Hemoglobin.
[15] T. Coates,et al. Improved R2* measurements in myocardial iron overload , 2006, Journal of magnetic resonance imaging : JMRI.
[16] D. Pennell,et al. Calibration of Myocardial T2* Values in Post-Mortem Hearts. , 2005 .
[17] J. Porter. Practical management of iron overload , 2001, British journal of haematology.
[18] D. Farmakis,et al. Cardiac status in well‐treated patients with thalassemia major , 2004, European journal of haematology.
[19] J Keegan,et al. Predictors of prognosis in severe chronic heart failure. , 1992, American heart journal.
[20] A. Piga,et al. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. , 2003, Haematologica.
[21] D. Pennell,et al. Left ventricular diastolic function compared with T2* cardiovascular magnetic resonance for early detection of myocardial iron overload in thalassemia major , 2005, Journal of magnetic resonance imaging : JMRI.
[22] David N. Firmin,et al. Intercentre Reproducibility of Magnetic Resonance T2* Measurements of Myocardial Iron in Thalassaemia , 2005, The International Journal of Cardiovascular Imaging.
[23] G. Link,et al. Exploring the "iron shuttle" hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture. , 2001, The Journal of laboratory and clinical medicine.
[24] C. McLaren,et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. , 1994, The New England journal of medicine.
[25] N. Olivieri,et al. Deferiprone (L1) chelates pathologic iron deposits from membranes of intact thalassemic and sickle red blood cells both in vitro and in vivo. , 1995, Blood.
[26] S. Colan,et al. Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major. , 1985, The New England journal of medicine.
[27] F. Galactéros. [Secondary iron overload]. , 1998, La Revue du praticien.
[28] D. Pennell,et al. A single breath‐hold multiecho T2* cardiovascular magnetic resonance technique for diagnosis of myocardial iron overload , 2003, Journal of magnetic resonance imaging : JMRI.
[29] Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial. , 2004 .
[30] J. H. MacMillan,et al. Survival in medically treated patients with homozygous beta-thalassemia. , 1994, The New England journal of medicine.
[31] Tzei-Yi Lin,et al. Safety monitoring of cardiac and hepatic systems in β‐thalassemia patients with chelating treatment in Taiwan * , 2003, European journal of haematology.
[32] S. Yusuf,et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators. , 1992, Circulation.
[33] N. Olivieri,et al. Secondary iron overload. , 2001, Hematology. American Society of Hematology. Education Program.
[34] D. Pennell,et al. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia , 2002, The Lancet.
[35] K. Ehlers,et al. The Effect of Subcutaneous Deferoxamine on the Cardiac Profile of Thalassemia Major: A Five‐Year Study , 1985, Annals of the New York Academy of Sciences.
[36] D N Firmin,et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. , 2001, European heart journal.
[37] Thomas D. Coates,et al. Cardiac Iron Determines Cardiac T2*, T2, and T1 in the Gerbil Model of Iron Cardiomyopathy , 2005, Circulation.
[38] P. Jarritt,et al. Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major. , 2004, Blood.
[39] A. Piga,et al. SURVIVAL AND CAUSES OF DEATH IN THALASSAEMIA MAJOR , 1989, The Lancet.
[40] D. Pennell,et al. Cardiovascular magnetic resonance , 2001, Heart.
[41] John B. Porter,et al. Myocardial T2* in Patients with Cardiac Failure Secondary to Iron Overload. , 2005 .
[42] V L Morgan,et al. Normal human right and left ventricular mass, systolic function, and gender differences by cine magnetic resonance imaging. , 1999, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance.
[43] T. Coates,et al. MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. , 2005, Blood.
[44] W. Hofmann,et al. WT1-Peptide Vaccination Shows High Immunogenicity and Clinical Activity in Patients with Acute Myeloid Leukemia. , 2005 .
[45] R M Whitlock,et al. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. , 1987, Circulation.
[46] D. Pennell,et al. Inter-Site Validation of a Single Breath Hold T2* MR Technique for Heart and Liver Iron Measurement. , 2005 .
[47] D. Levy,et al. Left ventricular dilatation and the risk of congestive heart failure in people without myocardial infarction. , 1997, The New England journal of medicine.
[48] Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). , 1987, The New England journal of medicine.
[49] J. Fleiss,et al. Risk stratification and survival after myocardial infarction. , 1983, The New England journal of medicine.
[50] O. Shalev,et al. Deferiprone ( L l ) Chelates Pathologic Iron Deposits From Membranes of Intact Thalassemic and Sickle Red Blood Cells Both In Vitro and In Vivo , 2002 .
[51] O. Olivieri,et al. Deferiprone therapy in homozygous human beta-thalassemia removes erythrocyte membrane free iron and reduces KCl cotransport activity. , 1999, The Journal of laboratory and clinical medicine.
[52] J. H. MacMillan,et al. Survival in Medically Treated Patients with Homozygous β-Thalassemia , 1994 .